Tokyo-Based LTT Bio-Pharma Names New President
This article was originally published in PharmAsia News
Japanese regenerative medicine company, Tokyo-based LTT Bio-Pharma names Iwao Suzuki as its new president, effective June 25. Current president Toshimi Nishiyama becomes the board director. Suzuki joined LTT in March as director of operations and the appointment came as a surprise to many. Several executives recently resigned following an investment scandal involving a LTT subsidiary. LTT's founder Yutaka Mizushima also died recently. (Click here for more - Japanese language
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.